{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001196","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.356361+00:00","generated_at":"2026-05-16T10:41:57.633814+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clene raises $28M in registered direct offering from Boxer, Coastlands, Vivo Capital","bullets":["Offering totals $28M in three tranches; initial $6.03M closed Jan 13, 2026 at $6.50/unit.","Additional tranches: $6.7M Series A warrants contingent on PDUFA date, $15.6M Series B on FDA approval.","Warrants exercise price adjustable based on stock price milestones; redeemable if in-the-money.","Investors include Boxer Capital, Coastlands Capital, Vivo Capital; BTIG as sole placement agent.","Proceeds expected to fund operations into early 2027, supporting NDA and potential CNM-Au8 commercialization in ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001196","json":"https://secwatch.observer/filing/0001437749-26-001196.json","markdown":"https://secwatch.observer/filing/0001437749-26-001196.md","text":"https://secwatch.observer/filing/0001437749-26-001196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926001196/0001437749-26-001196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926001196/clnn20260106_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:41:57.633814+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8292afa0af485f6d094e09f656a520199e65f416","claim":"Clene Inc. entered into Securities Purchase Agreement with certain institutional investors, existing stockholders of the Company, and certain of the Company's directors valued at $6.50 per unit (effective 2026-01-08).","evidence_excerpt":"On January 8, 2026, Clene Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, existing stockholders of the Company, and certain of the Company’s directors for the sale of (i) 928,333 shares of the Company’s common stock, par value $0.0001 per share (“common stock”), (ii) warrants to purchase up to 1,114,000 shares of the Company’s common stock (the “Series A Warrants”) and (iii) warrants to purchase up to 2,599,333 shares of the Company’s common stock (the “Series B Warrants,” and together with the Series A Warrants, the “Warrants”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774926001196/0001437749-26-001196-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional investors, existing stockholders of the Company, and certain of the Company's directors"},{"label":"Value","value":"$6.50 per unit"},{"label":"Effective","value":"2026-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}